Momelotinib During and After HCT in Myelofibrosis

• Status: NOT_YET_RECRUITING
• Trial end date: 2030-01-01

Summary

This is a single-center, open-label, phase I study to determine the safety and tolerability of momelotinib in patients with myelofibrosis during and after hematopoietic cell transplantation (HCT).

• Phase: PHASE1

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: GlaxoSmithKline
• Treatments: N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide